Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillin
- Development stage
- Phase 4
- Lead developer
- National Institutes of Health
- Administration
- Oral
01
Overview
Lactobacillin is a biologic product derived from the fermentation of skim milk by Lactobacillus acidophilus. It is classified as a digestive non-prescription drug in China. Its mechanism of action involves modulating the intestinal environment by forming a protective barrier, stimulating local immune responses, selectively inhibiting pathogenic bacteria, promoting beneficial flora, regulating intestinal electrolyte and water balance, and enhancing digestive function. It is primarily used for various gastrointestinal disorders and is currently under investigation for the prevention and treatment of oral mucositis.
- Brand names
- Lacidophilin TabletsLactoGuardProBioActiveSymbiotex
- Other names
- 乳酸菌素乳酸菌素片
Beyond the preview
Go deeper on Lactobacillin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillin.